2025EARLY TAVRTAVRIn 901 patients with asymptomatic severe aortic stenosis, early TAVR reduced death, stroke or unplanned cardiovascular hospitalisation compared with clinical surveillance.
2024NOTION-2TAVRIn 370 younger, low-risk patients (≤75 years) with severe aortic stenosis, transcatheter aortic-valve implantation was not shown non-inferior for 1-year death, stroke, or rehospitalisation compared with surgical aortic-valve replacement.
2023TRILUMINATETricuspidIn 350 patients with severe symptomatic tricuspid regurgitation, transcatheter tricuspid repair improved quality of life compared with medical therapy.
2022AVATARearly AVRIn 157 patients with asymptomatic severe aortic stenosis, early aortic valve replacement reduced death, MI, stroke, or HF hospitalisation compared with watchful waiting.
2022PROTECTED TAVRcerebral embolic protectionIn 3,000 patients undergoing transcatheter aortic-valve replacement, the Sentinel cerebral embolic protection device did not reduce periprocedural stroke compared with no embolic protection.
2019PARTNER 3TAVRIn 1,000 patients with severe AS at low surgical risk, TAVR with the SAPIEN 3 valve reduced death, stroke or rehospitalisation at one year versus surgical AVR.
2019Evolut Low RiskTAVRIn 1,468 patients with severe AS at low surgical risk, TAVR with a self-expanding valve was non-inferior to surgical aortic-valve replacement for death or disabling stroke at 2 years.
2018COAPTMitralIn 614 patients with HF and severe secondary mitral regurgitation, MitraClip plus GDMT reduced HF hospitalisation and all-cause mortality compared with GDMT alone.
2018MITRA-FRMitralIn 304 patients with heart failure and severe secondary mitral regurgitation, transcatheter mitral repair did not reduce death or heart-failure hospitalisation compared with medical therapy alone.
2016PARTNER 2ATAVRIn 2,032 intermediate-risk patients with severe aortic stenosis, transcatheter aortic-valve replacement was non-inferior for 2-year death or disabling stroke compared with surgical aortic-valve replacement.
2013RE-ALIGNAnticoagulationIn 252 patients with a mechanical aortic or mitral valve, dabigatran led to more thromboembolic events and major bleeding compared with warfarin.
2011EVEREST IIMitraClipIn 279 patients with grade 3+/4+ mitral regurgitation, percutaneous MitraClip repair was less effective at reducing death, mitral surgery, or residual MR at 12 months but safer than mitral valve surgery.
2010PARTNER 1BTAVRIn 358 patients with severe AS deemed inoperable, transcatheter aortic-valve replacement reduced all-cause mortality at 1 year compared with medical therapy.